Anterior Cruciate Ligament Reconstruction study: Tranexamic Acid
Official title The Effects of Tranexamic Acid on Joint Inflammation and Cartilage Health in Anterior Cruciate Ligament Injured Patients
ClinicalTrials.gov ID: NCT03552705
What this study is testing
What is Tranexamic Acid?
An investigational oral and intravenous medication being studied for its potential to reduce joint inflammation and improve joint health after anterior cruciate ligament reconstruction. It is designed to reduce bleeding by blocking the conversion of plasminogen to plasmin, thereby limiting fibrinolysis.
Also referred to as TXA.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to see whether giving Tranexamic Acid after ACL reconstruction can lower inflammation and improve joint health, possibly preventing arthritis.
- Who it's for
- Adults who have had ACL reconstruction surgery.
- What's involved
- Participants will receive Tranexamic Acid and will have regular follow‑up visits and joint health tests.
- Time commitment
- The study lasts about 10 years with periodic visits to monitor joint health.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 30
You may be able to join if
- age 18-30 years
- within 4 days of unilateral ACL injury
- presence of effusion/hemarthrosis.
You likely can't join if
- inflammatory arthritis, radiographic osteoarthritis (K-L Grade 2 or higher), gout/ pseudogout
- systemic or acute illness requiring medications
- concomitant knee injury aside from meniscus tear and MCL tear not requiring surgery
- prior surgery to either knee
- prior injury to either knee requiring crutches
- history of thromboembolic disease
See the full eligibility criteria
- age 18-30 years
- within 4 days of unilateral ACL injury
- presence of effusion/hemarthrosis.
- inflammatory arthritis, radiographic osteoarthritis (K-L Grade 2 or higher), gout/ pseudogout
- systemic or acute illness requiring medications
- concomitant knee injury aside from meniscus tear and MCL tear not requiring surgery
- prior surgery to either knee
- prior injury to either knee requiring crutches
- history of thromboembolic disease
- current use of combination hormonal contraception
- chronic NSAID use
- cortisone injection to either knee within the prior 3 months
- not indicated for or unable to undergo ACLR within 3 months of injury
The study team makes the final eligibility decision.
Where it is enrolling
- Stanford, California, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 30 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Stanford, California, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.